Please wait while the formulary information is being retrieved.
FAMOTIDINE (FAMOTIDINE)
- Dyspepsia
- Gastric ulcer
- Gastroesophageal reflux disease
- Heartburn
- Duodenal ulcer
- Dyspepsia prevention
- Erosive esophagitis
- Gastric hypersecretion with systemic mastocytosis
- Heartburn
- Heartburn prevention
- Maintenance of healing duodenal ulcer
- Multiple endocrine neoplasia
- Pathological gastric acid hypersecretory condition
- Reflux esophagitis
- Zollinger-ellison syndrome
- Pepcid Tablet
- Pepcid Ac Tablet
- Heartburn Relief (famotidine) Tablet
- Heartburn Prevention Tablet
- Famotidine Tablet
- Acid Reducer (famotidine) Tablet
- Acid Controller Tablet
- By Indication
20 mg tablet
- 1 tablet (20 mg) by oral route 2 times per day
40 mg tablet
- 1 tablet (40 mg) by oral route once daily at bedtime
10 mg tablet
- 1 tablet (10 mg) by oral route once daily as needed
20 mg tablet
- 1 tablet (20 mg) by oral route 2 times per day
(famotidine) 10 mg tablet
- 1 tablet (10 mg) by oral route once daily as needed
(famotidine) 20 mg tablet
- 1 tablet (20 mg) by oral route 2 times per day
10 mg tablet
- 1 tablet (10 mg) by oral route once daily as needed
20 mg tablet
- 1 tablet (20 mg) by oral route 2 times per day
10 mg tablet
- 1 tablet (10 mg) by oral route once daily as needed
20 mg tablet
- 1 tablet (20 mg) by oral route 2 times per day
40 mg tablet
- 1 tablet (40 mg) by oral route once daily at bedtime
(famotidine) 10 mg tablet
- 1 tablet (10 mg) by oral route once daily as needed
(famotidine) 20 mg tablet
- 1 tablet (20 mg) by oral route 2 times per day
10 mg tablet
- 1 tablet (10 mg) by oral route once daily as needed
20 mg tablet
- 1 tablet (20 mg) by oral route 2 times per day
ler 10 mg tablet
- 1 tablet (10 mg) by oral route once daily as needed
ler 20 mg tablet
- 1 tablet (20 mg) by oral route 2 times per day
Duodenal ulcer
- 1 tablet (20 mg) by oral route every 12 hours
- 1 tablet (20 mg) by oral route 2 times per day
- 1 tablet (40 mg) by oral route once daily at bedtime
- 2 tablets (40 mg) by oral route once daily at bedtime
Dyspepsia
- 1 tablet (10 mg) by oral route once daily as needed
- 1 tablet (10 mg) by oral route 2 times per day as needed
- 2 tablets (20 mg) by oral route every 12 hours
Dyspepsia prevention
- 1 tablet (10 mg) by oral route once daily as needed
- 1 tablet (10 mg) by oral route 2 times per day as needed
- 2 tablets (20 mg) by oral route every 12 hours
Erosive esophagitis
- 1 tablet (20 mg) by oral route 2 times per day
- 2 tablets (40 mg) by oral route 2 times per day
- 1 tablet (40 mg) by oral route 2 times per day
Gastric hypersecretion with systemic mastocytosis
- 1 tablet (20 mg) by oral route every 6 hours
- 2 tablets (40 mg) by oral route every 6 hours
- 1 tablet (40 mg) by oral route every 6 hours
- 2 tablets (80 mg) by oral route every 6 hours
Gastric ulcer
- 1 tablet (40 mg) by oral route once daily at bedtime
- 2 tablets (40 mg) by oral route once daily at bedtime
Gastroesophageal reflux disease
- 1 tablet (20 mg) by oral route every 12 hours
- 1 tablet (20 mg) by oral route 2 times per day
- 1 tablet (40 mg) by oral route 2 times per day
- 1 tablet (40 mg) by oral route once daily at bedtime
- 1 tablet (40 mg) by oral route every 12 hours
- 2 tablets (40 mg) by oral route once daily at bedtime
Heartburn
- 1 tablet (10 mg) by oral route once daily as needed
- 1 tablet (10 mg) by oral route 2 times per day as needed
Heartburn prevention
- 1 tablet (10 mg) by oral route once daily as needed
- 1 tablet (10 mg) by oral route 2 times per day as needed
Maintenance of healing duodenal ulcer
- 1 tablet (20 mg) by oral route once daily at bedtime
Multiple endocrine neoplasia
- 1 tablet (20 mg) by oral route every 6 hours
- 2 tablets (40 mg) by oral route every 6 hours
- 1 tablet (40 mg) by oral route every 6 hours
- 2 tablets (80 mg) by oral route every 6 hours
Pathological gastric acid hypersecretory condition
- 1 tablet (20 mg) by oral route every 6 hours
- 2 tablets (40 mg) by oral route every 6 hours
- 1 tablet (40 mg) by oral route every 6 hours
- 2 tablets (80 mg) by oral route every 6 hours
Reflux esophagitis
- 1 tablet (20 mg) by oral route 2 times per day
- 2 tablets (40 mg) by oral route 2 times per day
- 1 tablet (40 mg) by oral route 2 times per day
Upper GI bleed
- 1 tablet (20 mg) by oral route every 12 hours
- 1 tablet (20 mg) by oral route 2 times per day
Zollinger-ellison syndrome
- 1 tablet (20 mg) by oral route every 6 hours
- 2 tablets (40 mg) by oral route every 6 hours
- 1 tablet (40 mg) by oral route every 6 hours
- 2 tablets (80 mg) by oral route every 6 hours
- None
Contraindicated
- itraconazole
- ketoconazole
- Onmel
- Sporanox
- Sporanox Pulsepak
- tizanidine
- Zanaflex
Severe
Moderate
- Adderall
- Adderall Xr
- Amphetamine Salt Combo
- atazanavir
- Ceftin
- cefuroxime axetil
- Complera
- Dexedrine Spansule
- dextroamphetamine
- dextroamphetamine-amphetamine
- Edurant
- emtricitab-rilpivirine-tenofov
- Isentress
- Procentra
- raltegravir
- Reyataz
- rilpivirine
- Zenzedi
- None
Contraindicated
- Chronic kidney disease stage 3A (moderate) GFR 45-59
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Gastric cancer
Severe
Moderate
- Kidney disease with likely reduction in GFR
FAMOTIDINE (FAMOTIDINE)
- Dyspepsia
- Gastric ulcer
- Gastroesophageal reflux disease
- Heartburn
- Duodenal ulcer
- Dyspepsia prevention
- Erosive esophagitis
- Gastric hypersecretion with systemic mastocytosis
- Heartburn
- Heartburn prevention
- Maintenance of healing duodenal ulcer
- Multiple endocrine neoplasia
- Pathological gastric acid hypersecretory condition
- Reflux esophagitis
- Zollinger-ellison syndrome
- None
- Constipation
- Diarrhea
- Dizziness
- Headache disorder
More Frequent
Severe
Less Severe
- None
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Agranulocytosis
- Anaphylaxis
- Anemia
- Angioedema
- Atrioventricular block
- Bronchospastic pulmonary disease
- Cardiac arrhythmia
- Dyspnea
- Hepatitis
- Hypotension
- Increased alanine transaminase
- Increased aspartate transaminase
- Interstitial pneumonitis
- Leukopenia
- Neutropenic disorder
- Obstructive hyperbilirubinemia
- Pancytopenia
- Psychiatric disorder
- Rhabdomyolysis
- Seizure disorder
- Skin rash
- Stevens-johnson syndrome
- Thrombocytopenic disorder
- Toxic epidermal necrolysis
- Urticaria
Less Severe
- Acne vulgaris
- Acute abdominal pain
- Acute confusion
- Agitation
- Allergic conjunctivitis
- Alopecia
- Anorexia
- Arthralgias
- Cramps
- Delirium
- Drowsy
- Dry skin
- Dysgeusia
- Facial edema
- Fatigue
- Fever
- Flushing
- General weakness
- Hallucinations
- Insomnia
- Lethargy
- Nausea
- Paresthesia
- Pruritus of skin
- Tinnitus
- Vomiting
- Xerostomia
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Famotidine
- Severity Level:
2
- Additional Notes: Insufficient human data available.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Famotidine
Limited data suggest low amounts excreted, with no resulting effect on infant
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | Limited data suggest low amounts excreted, with no resulting effect on infant |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Famotidine
Neuro/Psych-Avoid in older adults with or at high risk of delirium because of inducing or worsening delirium. Avoid in elderly with dementia or cognitive impairment. Renal-Dose adjustment may be required for CrCL<50 mL/min. to minimize CNS effects (e.g., mental status changes).
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | N | Y | N | N |
BEERS: Y HEDIS: N STOPP: N
No Known Risk
None
- None
| Duodenal ulcer | |
| K26 | Duodenal ulcer |
| K26.0 | Acute duodenal ulcer with hemorrhage |
| K26.1 | Acute duodenal ulcer with perforation |
| K26.2 | Acute duodenal ulcer with both hemorrhage and perforation |
| K26.3 | Acute duodenal ulcer without hemorrhage or perforation |
| K26.4 | Chronic or unspecified duodenal ulcer with hemorrhage |
| K26.5 | Chronic or unspecified duodenal ulcer with perforation |
| K26.6 | Chronic or unspecified duodenal ulcer with both hemorrhage and perforation |
| K26.7 | Chronic duodenal ulcer without hemorrhage or perforation |
| K26.9 | Duodenal ulcer, unspecified as acute or chronic, without hemorrhage or perforation |
| Dyspepsia | |
| K30 | Functional dyspepsia |
| Dyspepsia prevention | |
| K30 | Functional dyspepsia |
| Erosive esophagitis | |
| K22.1 | Ulcer of esophagus |
| K22.10 | Ulcer of esophagus without bleeding |
| K22.11 | Ulcer of esophagus with bleeding |
| Gastric hypersecretion with systemic mastocytosis | |
| C96.21 | Aggressive systemic mastocytosis |
| D47.02 | Systemic mastocytosis |
| K31.89 | Other diseases of stomach and duodenum |
| Gastric ulcer | |
| K25 | Gastric ulcer |
| K25.0 | Acute gastric ulcer with hemorrhage |
| K25.1 | Acute gastric ulcer with perforation |
| K25.2 | Acute gastric ulcer with both hemorrhage and perforation |
| K25.3 | Acute gastric ulcer without hemorrhage or perforation |
| K25.4 | Chronic or unspecified gastric ulcer with hemorrhage |
| K25.5 | Chronic or unspecified gastric ulcer with perforation |
| K25.6 | Chronic or unspecified gastric ulcer with both hemorrhage and perforation |
| K25.7 | Chronic gastric ulcer without hemorrhage or perforation |
| K25.9 | Gastric ulcer, unspecified as acute or chronic, without hemorrhage or perforation |
| Gastroesophageal reflux disease | |
| K21 | Gastro-esophageal reflux disease |
| K21.0 | Gastro-esophageal reflux disease with esophagitis |
| K21.9 | Gastro-esophageal reflux disease without esophagitis |
| Heartburn | |
| R12 | Heartburn |
| Maintenance of healing duodenal ulcer | |
| K26 | Duodenal ulcer |
| K26.0 | Acute duodenal ulcer with hemorrhage |
| K26.1 | Acute duodenal ulcer with perforation |
| K26.2 | Acute duodenal ulcer with both hemorrhage and perforation |
| K26.3 | Acute duodenal ulcer without hemorrhage or perforation |
| K26.4 | Chronic or unspecified duodenal ulcer with hemorrhage |
| K26.5 | Chronic or unspecified duodenal ulcer with perforation |
| K26.6 | Chronic or unspecified duodenal ulcer with both hemorrhage and perforation |
| K26.7 | Chronic duodenal ulcer without hemorrhage or perforation |
| K26.9 | Duodenal ulcer, unspecified as acute or chronic, without hemorrhage or perforation |
| Multiple endocrine neoplasia | |
| E31.2 | Multiple endocrine neoplasia [MEn] syndromes |
| E31.20 | Multiple endocrine neoplasia [MEn] syndrome, unspecified |
| E31.21 | Multiple endocrine neoplasia [MEn] type I |
| E31.22 | Multiple endocrine neoplasia [MEn] type IIA |
| E31.23 | Multiple endocrine neoplasia [MEn] type IIB |
| Pathological gastric acid hypersecretory condition | |
| K31.89 | Other diseases of stomach and duodenum |
| Reflux esophagitis | |
| K21.0 | Gastro-esophageal reflux disease with esophagitis |
| Zollinger-ellison syndrome | |
| E16.4 | Increased secretion of gastrin |
| 0-9 | A-Z |
|---|---|
| C96.21 | Aggressive systemic mastocytosis |
| D47.02 | Systemic mastocytosis |
| E16.4 | Increased secretion of gastrin |
| E31.2 | Multiple endocrine neoplasia [MEn] syndromes |
| E31.20 | Multiple endocrine neoplasia [MEn] syndrome, unspecified |
| E31.21 | Multiple endocrine neoplasia [MEn] type I |
| E31.22 | Multiple endocrine neoplasia [MEn] type IIA |
| E31.23 | Multiple endocrine neoplasia [MEn] type IIB |
| K21 | Gastro-esophageal reflux disease |
| K21.0 | Gastro-esophageal reflux disease with esophagitis |
| K21.0 | Gastro-esophageal reflux disease with esophagitis |
| K21.9 | Gastro-esophageal reflux disease without esophagitis |
| K22.1 | Ulcer of esophagus |
| K22.10 | Ulcer of esophagus without bleeding |
| K22.11 | Ulcer of esophagus with bleeding |
| K25 | Gastric ulcer |
| K25.0 | Acute gastric ulcer with hemorrhage |
| K25.1 | Acute gastric ulcer with perforation |
| K25.2 | Acute gastric ulcer with both hemorrhage and perforation |
| K25.3 | Acute gastric ulcer without hemorrhage or perforation |
| K25.4 | Chronic or unspecified gastric ulcer with hemorrhage |
| K25.5 | Chronic or unspecified gastric ulcer with perforation |
| K25.6 | Chronic or unspecified gastric ulcer with both hemorrhage and perforation |
| K25.7 | Chronic gastric ulcer without hemorrhage or perforation |
| K25.9 | Gastric ulcer, unspecified as acute or chronic, without hemorrhage or perforation |
| K26 | Duodenal ulcer |
| K26 | Duodenal ulcer |
| K26.0 | Acute duodenal ulcer with hemorrhage |
| K26.0 | Acute duodenal ulcer with hemorrhage |
| K26.1 | Acute duodenal ulcer with perforation |
| K26.1 | Acute duodenal ulcer with perforation |
| K26.2 | Acute duodenal ulcer with both hemorrhage and perforation |
| K26.2 | Acute duodenal ulcer with both hemorrhage and perforation |
| K26.3 | Acute duodenal ulcer without hemorrhage or perforation |
| K26.3 | Acute duodenal ulcer without hemorrhage or perforation |
| K26.4 | Chronic or unspecified duodenal ulcer with hemorrhage |
| K26.4 | Chronic or unspecified duodenal ulcer with hemorrhage |
| K26.5 | Chronic or unspecified duodenal ulcer with perforation |
| K26.5 | Chronic or unspecified duodenal ulcer with perforation |
| K26.6 | Chronic or unspecified duodenal ulcer with both hemorrhage and perforation |
| K26.6 | Chronic or unspecified duodenal ulcer with both hemorrhage and perforation |
| K26.7 | Chronic duodenal ulcer without hemorrhage or perforation |
| K26.7 | Chronic duodenal ulcer without hemorrhage or perforation |
| K26.9 | Duodenal ulcer, unspecified as acute or chronic, without hemorrhage or perforation |
| K26.9 | Duodenal ulcer, unspecified as acute or chronic, without hemorrhage or perforation |
| K30 | Functional dyspepsia |
| K30 | Functional dyspepsia |
| K31.89 | Other diseases of stomach and duodenum |
| K31.89 | Other diseases of stomach and duodenum |
| R12 | Heartburn |
Formulary Reference Tool